ClinicalTrials.Veeva

Menu

The Effect of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability (Promi2)

W

Wageningen University

Status

Unknown

Conditions

Migraine

Treatments

Dietary Supplement: EcologicBarrier
Other: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT02342262
NL46401.081.13

Details and patient eligibility

About

RATIONALE: The prevalence of migraine is higher in patients with various intestinal diseases. An explanation could be that migraine is caused by a 'leaky gut': an increased intestinal permeability that allows food particles to pass the gastrointestinal wall. Probiotics may be able to improve intestinal barrier function.

OBJECTIVE: To test whether probiotics, as adjuvant therapy, can reduce incidence and severity of migraine attacks by reducing intestinal permeability.

STUDY DESIGN: 12-week placebo-controlled randomized double-blind intervention with selected probiotics.

STUDY POPULATION: Adults who experience at least 4 migraine attacks per month. INTERVENTION: Subjects will receive either one daily dose of 2 g of Ecologic® Barrier or 2 grams of the placebo, containing only the carrier material (both provided by Winclove Probiotics).

MAIN STUDY PARAMETERS/ENDPOINTS: Incidence and severity of migraine attacks, measured by diaries and validated headache questionnaires will be measured at baseline and after 4, 8, and 12 weeks of probiotic/placebo administration. Secondary, intestinal permeability will be measured by the lactulose/mannitol absorption test in urine (screening, baseline and 12 weeks) and by fecal zonulin (baseline, 4, 8, and 12 weeks). Inflammation will be assessed from blood C-reactive protein and cytokine concentrations (baseline, 4, 8, and 12 weeks). Fecal samples will also be used for microbial analysis.

Enrollment

80 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects confirm to have migraine characterized by :

    • Recurrent attacks of moderate to severe headaches, often one-sided and pounding, often with nausea and/or vomiting, aggravated by physical activity
    • Sensitivity for light or sounds is possible but not exclusive.
    • Attacks last for 4 to 72 hours.
  • Self-reported frequency of migraine attacks (or days) at least 4 per month

  • Fairly predictable/stable pattern of migraine attacks (frequency, duration, intensity)

  • Age ≥ 18 years

  • Good overall health (self-reported in medical questionnaire)

Exclusion criteria

  • Migraine patients who suffer from chronic daily migraine/headaches
  • Migraine patients who suffer from medication-dependent headaches
  • Subjects who suffer from cluster headache or tension-type headaches
  • Subjects who used antibiotics up to two months before the start of the study
  • Subjects who are unwilling to stop taking probiotics other than study products
  • Patients with a chronic use of non steroid anti inflammatory drugs (because of increased gut permeability)
  • Patients with inflammatory bowel diseases (because of increased gut permeability)
  • Pregnancy or lactation (because of their possible effect on migraine incidence)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

80 participants in 2 patient groups, including a placebo group

Probiotics
Experimental group
Description:
EcologicBarrier, 5x10E9 cfu/day
Treatment:
Dietary Supplement: EcologicBarrier
Placebo
Placebo Comparator group
Description:
carrier material of Ecologic Barrier, not containing bacterial strains
Treatment:
Other: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems